TX-SOFTSERVE
27.10.2020 12:02:04 CET | Business Wire | Press release
SoftServe , a leading digital authority and consulting company and Premier Consulting Partner in the Amazon Web Services (AWS) Partner Network (APN), announces it has achieved AWS SaaS Competency status. The designation recognizes SoftServe’s experience helping organizations design and build Software-as-a-Service (SaaS) and cloud-native solutions on AWS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005054/en/
In addition to the AWS SaaS Competency designation, SoftServe has also previously achieved AWS Data & Analytics Competency, AWS DevOps Competency, AWS Financial Services Competency, and AWS Retail Competency designations.
“By achieving AWS SaaS Competency status, we are committed to technical proficiency and customer success in the AWS Partner Network, enabling our clients with the most reliable and cost-effective SaaS solutions that are scalable, secure, and globally accessible,” said Andrew Greene - Associate Vice President, Global Partnerships & Alliances at SoftServe. “SoftServe has a proven track record of helping global organizations migrate, design, and build SaaS and cloud-native solutions on AWS through architecture reviews, technology R&D advisory services, security assessments; as well as full scope application migrations, modernizations, re-architectures, and new builds for enterprise and high-tech ISV clients.”
Using AWS and a well-architected multi-account strategy, Gotransverse and SoftServe implemented a multi-tenant SaaS solution to quickly develop and regularly update its customers’ services and components.
“SoftServe was instrumental in supporting our ability to automate the AWS data center creation process where we can go from nothing to a ready-to-provision data center with just a few keystrokes using Terraform and Ansible on top of the AWS API stack,” said Paul Tindall, CTO at Gotransverse. “Prior to this, building a new data center was very manual and error-prone. During this automation process, we were also able to go from self-managing services such as Redis and Elasticsearch to using AWS provided equivalents (Amazon ElastiCache and Amazon Elasticsearch). The development of this capability has more than paid for itself as we have expanded our geographic footprint across the globe with our launches of additional data centers in Australia, Europe, and North America. We look forward to working with SoftServe as we migrate our microservices layer to Amazon Kubernetes Service (Amazon EKS) and explore AWS artificial intelligence (AI) and machine learning (ML) offerings for enhancements to our product.”
AWS enables reliable, scalable, and secure solutions for startups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise. AWS SaaS Competency Partners help customers reduce friction when migrating off legacy applications and establish foundations required to build SaaS solutions successfully on AWS. They also write production application code and design and implement end-to-end solutions architecture for cloud-native products on AWS.
SoftServe’s Cloud-enabled services guide you from vision to execution in your SaaS journey, supporting key competencies in streamlined onboarding procedures, identity and access management, tenant isolation, and data partitioning. To learn more about SoftServe’s SaaS offerings on AWS, please visit www.softserveinc.com/en-us/aws-saas-enablement .
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005054/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom